We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
BTG | LSE:BGC | London | Ordinary Share | GB0001001592 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 387.50 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
29/5/2012 08:12 | excellent progress each day | doctor 69 | |
28/5/2012 22:30 | why oh why would a massive company go to such efforts at this meeting . Surely ZTIGA ia heading to be a $2b blockbuster much quikcer than anyone thought. Just think 3% net to BTG | doctor 69 | |
28/5/2012 16:31 | bargain looks like persistant interest from some people , great share | doctor 69 | |
28/5/2012 12:36 | Looks like someone expects news every morning before it settles back. | bargainbob | |
25/5/2012 13:02 | RNS TIDMBGC BTG PLC 25 May 2012 BTG to present at the Jefferies Global Healthcare Conference London, UK, 25 May 2012: BTG plc (LSE: BGC), the specialist healthcare company, today announces that Louise Makin, CEO, will be presenting at the Jefferies Global Healthcare Conference in New York, US on Thursday, 7 June at 9.00am EDT (New York time), 2.00pm BST (London time). The presentation will be uploaded to the BTG's website in the Investor/Results and Presentations area shortly after the presentation has concluded to ensure access for anyone unable to attend in person. | aquila2001 | |
25/5/2012 08:29 | going up strongly and some volume, interesting | doctor 69 | |
23/5/2012 17:23 | This was a solid performance in a really depressed market. This will start to climb once some sort of stability returns. | superbarnet | |
22/5/2012 21:36 | LONDON (Dow Jones)-- BTG PLC (BGC.LN), the U.K specialty pharmaceutical company, is looking to spend the roughly GBP40 million it has at its disposal on bringing in specialty, late-stage drugs that will help to continue its growth. "We are constantly looking at adding to our portfolio" the company's Chief Executive Officer Louise Makin told Dow Jones Newswires in an interview this week, adding that BTG would ideally like to stick with specialty pharmaceutical products. | bill hunt | |
22/5/2012 20:31 | i have noticed in the past after btg results that there is often a pause for a few days and then the buying starts. Hope this is not the kiss of death. | doctor 69 | |
22/5/2012 17:33 | wywcu1 Three buy notes BB says buy up to 4.00 | bargainbob | |
22/5/2012 15:44 | This rise is really positive as people digest the results. The march north should continue. | superbarnet | |
22/5/2012 10:21 | We have two BUY notices today - namely: - J.P.Morgan Cazenove buy with a revised target of £4.60 up from £4.15 - HB Markets buy but no target given. | wywcu1 | |
22/5/2012 06:31 | And you have a director buying shares | doctor 69 | |
21/5/2012 19:59 | Impressive stuff! Louise Makin will become a household name - mark my words! | cockneytrader | |
21/5/2012 18:41 | A share price can be slashed even when good results are reported. It all depends on the analysts' expectations. I am delighted at the performance today as the price was little changed. The graph shows the long term direction and i will be adding over the next few weeks. | superbarnet | |
21/5/2012 18:19 | Alord The results did impress buyers , just they will come another day to buy . No one can fail to be impressed by these results | doctor 69 | |
21/5/2012 17:22 | Crazy market! Why can't we celebrate and reward a SUCCESSFUL BRITISH COMPANY!!! | fhmktg | |
21/5/2012 10:45 | I am doubting that Astra Zeneca will be interested to buy BTG: 1 They have already license agreement for CytoFab . 2 The rest of BTG pipeline is not for Astra's strategy. 3 I think that BTG will be looking around to buy , like LM mentioned at presentation today. So IMO there will be no bid for BTG soon. SP hopefully will be slowly growing after consolidation. PS1 Jefferies has reiterated its buy recommendation and 410p target price for specialist healthcare company BTG (LSE: BGC.L - news) after the firm's full-year results this morning. PS2 BTG (LSE: BGC.L - news) : Finncap raises to hold from sell ANYBODY KNOWS WHAT RECOMMENDATIONS ISSUED OTHER BROKERS ? THANKS IN ADVANCE ))) I think results didnt impress buyers unfortunately despite better market today ((( | a1ord53 | |
21/5/2012 07:39 | Solid results ahead of expectations with significant upside in coming years. Well done Louise & co! Looking forward to re-commencing the rise back up towards where it belongs. "On the mountains of truth you can never climb in vain: either you will reach a point higher up today, or you will be training your powers so that you will be able to climb higher tomorrow." Nietzsche Good luck all. | moretimeforlife | |
21/5/2012 07:38 | very strong results , the zytiga sales have really taken off and this looks like a £30m plus earner for this year. Really impressive and if you think only a a couple of monnths ago we expected sales of £160m this year and now we get £197m . stunnning | doctor 69 | |
21/5/2012 07:25 | A good read in the results everything positive. Apart from cautionary notes. Above 160 to 190 guidance. | bill hunt | |
20/5/2012 22:27 | results time at btg is always little more than a damp squib. will tomorrow be any different? i do hope so! | cockneytrader | |
20/5/2012 19:32 | Knock knock.... FT online May 20, 2012 4:50 pm AstraZeneca looks to revive experimental drugs AstraZeneca plans to seal several new deals this year to fill its flagging pipeline of experimental medicines, which may be funded jointly with private investors. Martin Mackay, president of research and development at the Anglo-Swedish pharmaceutical group, told the Financial Times he would be "personally disappointed" if he had not concluded new agreements before the end of 2012. He said that could include partnerships with other large drug companies, full acquisition of smaller quoted biotech companies and licensing deals for specific drugs developed by others. | waterloo01 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions